Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial - Takeaways - MDSpire

Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial

  • By

  • Rebecca McKetin

  • Steven Shoptaw

  • Lucy Saunders

  • Long Nguyen

  • Philip J. Clare

  • Gregory J. Dore

  • Alyna Turner

  • Olivia M. Dean

  • Peter J. Kelly

  • Shalini Arunogiri

  • Juanita Koeijers

  • Tayla J. Degan

  • Louisa Degenhardt

  • Michael Farrell

  • David Goodman-Meza

  • Barbara Sinclair

  • David Reid

  • Frank Cordaro

  • Harry Hill

  • Robert Lundin

  • Jeremy Hayllar

  • Michael Christmass

  • Willy Liaw

  • Danica Liu

  • Amelia Woods

  • Blaire Brewerton

  • Ellie Holyoak

  • Brian Tid-Fung Wu

  • Hayley Maher

  • Noni O’Dea

  • Joel Keygan

  • Ava Kontogiannis

  • Lily Palmer

  • Caity Morrison

  • Anna Wrobel

  • Bec Hyland

  • Gift Kiden

  • Vanessa Romeo

  • Khine Wut Yee Kyaw

  • Marianne Byrne

  • Samantha Colledge-Frisby

  • Emma Zahra

  • Michael Berk

  • June 1, 2026

  • 0 min

Share

  • 1

    Methamphetamine use disorder affects approximately 7.4 million people globally, leading to significant health risks and drug-related deaths.

  • 2

    Mirtazapine, a tetracyclic antidepressant, shows promise in reducing methamphetamine's effects and addressing associated dysregulation.

  • 3

    Two phase 2 trials indicated a 14% difference in methamphetamine-positive urine tests between mirtazapine and placebo after 12 weeks.

  • 4

    A phase 3 randomized clinical trial was conducted in Australia to evaluate mirtazapine's effectiveness and safety in a diverse population.

  • 5

    The primary outcome of the trial was the change in self-reported days of methamphetamine use over 28 days, assessed at multiple time points.

Original Source(s)

Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial

  • by Rebecca McKetin, Steven Shoptaw, Lucy Saunders, Long Nguyen, Philip J. Clare, Gregory J. Dore, Alyna Turner, Olivia M. Dean, Peter J. Kelly, Shalini Arunogiri, Juanita Koeijers, Tayla J. Degan, Louisa Degenhardt, Michael Farrell, David Goodman-Meza, Barbara Sinclair, David Reid, Frank Cordaro, Harry Hill, Robert Lundin, Jeremy Hayllar, Michael Christmass, Willy Liaw, Danica Liu, Amelia Woods, Blaire Brewerton, Ellie Holyoak, Brian Tid-Fung Wu, Hayley Maher, Noni O’Dea, Joel Keygan, Ava Kontogiannis, Lily Palmer, Caity Morrison, Anna Wrobel, Bec Hyland, Gift Kiden, Vanessa Romeo, Khine Wut Yee Kyaw, Marianne Byrne, Samantha Colledge-Frisby, Emma Zahra, Michael Berk

  • June 1, 2026

Related Content

Wastewater Study Tracks Illicit Drug Use Across England

A year-long LC-MS/MS study suggests wastewater surveillance can reveal shifts in drug consumption linked to public events, weekends, and law enforcement activity

  • May 27, 2026

  • 3 min
Long-term psychological and functional outcomes after hepatitis C eradication with direct-acting antivirals: an 80-month follow-up study

Depressive symptoms and risk of incident activities of daily living disability among older adults with symptomatic arthritis